123 related articles for article (PubMed ID: 9949952)
1. Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections.
Schubert J; Zens W; Weissbrich B
J Clin Virol; 1998 Dec; 11(3):161-72. PubMed ID: 9949952
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of three ELISA techniques and an indirect immunofluorescence assay for the serological diagnosis of Epstein-Barr virus infection.
Debyser Z; Reynders M; Goubau P; Desmyter J
Clin Diagn Virol; 1997 May; 8(1):71-81. PubMed ID: 9248660
[TBL] [Abstract][Full Text] [Related]
4. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
5. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology.
Bauer G
Clin Lab; 2001; 47(5-6):223-30. PubMed ID: 11405600
[TBL] [Abstract][Full Text] [Related]
6. The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis.
Weissbrich B
J Med Virol; 1998 Feb; 54(2):145-53. PubMed ID: 9496374
[TBL] [Abstract][Full Text] [Related]
7. Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology.
Andersson A; Vetter V; Kreutzer L; Bauer G
J Med Virol; 1994 Jul; 43(3):238-44. PubMed ID: 7931184
[TBL] [Abstract][Full Text] [Related]
8. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state.
Sener AG; Afsar I; Pinar E
J Virol Methods; 2009 Aug; 159(2):300-2. PubMed ID: 19406156
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic importance of heterophile antibodies and immunoglobulins IgA, IgE, IgM and low-avidity IgG against Epstein-Barr virus capsid antigen in children.
Votava M; Bartosová D; Krchnáková A; Crhová K; Kubinová L
Acta Virol; 1996 Apr; 40(2):99-101. PubMed ID: 8886119
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the new ARCHITECT EBV assays considering different testing algorithms.
Sickinger E; Berth M; Vockel A; Braun HB; Oer M; Buenning C
Diagn Microbiol Infect Dis; 2014 Jul; 79(3):310-6. PubMed ID: 24809858
[TBL] [Abstract][Full Text] [Related]
13. The role of IgG avidity determination in diagnosis of Epstein-Barr virus infection in immunocompetent and immunocompromised patients.
Vilibic-Cavlek T; Ljubin-Sternak S; Kos L; Mlinaric-Galinovic G
Acta Microbiol Immunol Hung; 2011 Dec; 58(4):351-7. PubMed ID: 22207292
[TBL] [Abstract][Full Text] [Related]
14. Analytical performance evaluation of the Elecsys Epstein-Barr virus immunoassay panel.
Schulte-Spechtel U; Berth M; Lauseker-Hao Y; Meyer-Schlinkmann K; Bohnert M; Jochum S; Schuhmann K
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115443. PubMed ID: 34304105
[TBL] [Abstract][Full Text] [Related]
15. Avidity of EBV VCA-specific IgG antibodies: distinction between recent primary infection, past infection and reactivation.
Gray JJ
J Virol Methods; 1995 Mar; 52(1-2):95-104. PubMed ID: 7769043
[TBL] [Abstract][Full Text] [Related]
16. Serodiagnosis of Epstein-Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion.
Hinderer W; Lang D; Rothe M; Vornhagen R; Sonneborn HH; Wolf H
J Clin Microbiol; 1999 Oct; 37(10):3239-44. PubMed ID: 10488185
[TBL] [Abstract][Full Text] [Related]
17. Serological and clinical findings in patients with serological evidence of reactivated Epstein-Barr virus infection.
Obel N; Høier-Madsen M; Kangro H
APMIS; 1996 Jun; 104(6):424-8. PubMed ID: 8774671
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus serostatus: no difference despite aberrant patterns in athletes and control group.
Pottgiesser T; Wolfarth B; Schumacher YO; Bauer G
Med Sci Sports Exerc; 2006 Oct; 38(10):1782-91. PubMed ID: 17019300
[TBL] [Abstract][Full Text] [Related]
19. [Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].
De Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):618-20. PubMed ID: 22854635
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
